Andecaliximab

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

65 competitors in Spinal Cord Injury

#DrugCompanyPhaseTrials

1

Zometa

Pfizer

Approved

52

Keppra

UCB

Approved

13

Calciferol

Jazz Pharmaceuticals

Approved

—4

Lioresal

Novartis

Approved

—5

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

46

Prolia

OOrganon and Co

Approved

27

Xarelto

WWim Janssens

Approved

18

Botox

RRevance Therapeutics, Inc.

Approved

19

Spiriva

Boehringer Ingelheim

Approved

—10

Andriol

AAuxilium

Approved

—Show 38 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Gastroesophageal Junction Adenocarcinoma3 trials

Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

Completed·Gilead·Phase 3·NCT02545504·432 enrolled

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

Terminated·Gilead·Phase 1·NCT02862535·36 enrolled

Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

Completed·Gilead·Phase 2·NCT02864381·144 enrolled

Ulcerative Colitis2 trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

Completed·Gilead·Phase 1·NCT01831427·74 enrolled

Safety and Efficacy of Andecaliximab (GS-5745) in Adults With Moderately to Severely Active Ulcerative Colitis

Terminated·Gilead·Phase 2/3·NCT02520284·165 enrolled

Advanced Solid Tumors1 trial

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors

Completed·Gilead·Phase 1·NCT01803282·236 enrolled

Rheumatoid Arthritis1 trial

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Terminated·Gilead·Phase 2·NCT02862574·15 enrolled

Cystic Fibrosis1 trial

Effect of Andecaliximab on FEV1 in Adults With Cystic Fibrosis

Terminated·Gilead·Phase 2·NCT02759562·6 enrolled

4 more indications

Safety and Efficacy1 trial

Safety and Efficacy of Andecaliximab in Participants With Moderately to Severely Active Crohn's Disease

Terminated·Gilead·Phase 2·NCT02405442·187 enrolled

Spinal Cord Injury1 trial

A Study of Andecaliximab in People With Spinal Cord Injury at Risk for Bone Growth Outside of the Normal Skeleton.

Recruiting·AAshibio Inc·Phase 1/2·NCT07024407·10 enrolled

Fibrodysplasia Ossificans Progressiva1 trial

A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)

Active, not recruiting·AAshibio Inc·Phase 2/3·NCT06508021·92 enrolled

Chronic Obstructive Pulmonary Disease1 trial

Safety, Tolerability, and Pharmacokinetics of Andecaliximab in Adults With Chronic Obstructive Pulmonary Disease (COPD)

Completed·Gilead·Phase 1·NCT02077465·11 enrolled

Details

Drug Info

Related News